Shionogi-ViiV Healthcare LLC's HIV drug dolutegravir beat Gilead Sciences Inc.'s Atripla in a Phase III trial in treatment-naive adults with HIV-1 infection. Initial results showed that 88 percent of patients receiving dolutegravir with Kivexa/Epzicom (abacavir/lamivudine) were virologically suppressed, compared to 81 percent on Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate).
Biolex Therapeutics Inc., of Pittsboro, N.C., filed for bankruptcy liquidation, according to its partner OctoPlus N.V. The company aimed to make a better interferon for hepatitis C virus (HCV), and to that end burned through $185 million in venture capital since it was founded in 1997.
Audeo Oncology Inc. filed for a $60 million initial public offering (IPO) to support clinical trials of its products based on hyaluronic acid chemotransport technology (HyACT) for cancer. The HyACT platform is designed to boost the effectiveness of cancer drugs without increasing toxicity.
Bristol Myers Squibb Co., of New York, will realize operating synergies and tax benefits in addition to gaining access to Amylin Pharmaceuticals Inc.'s GLP-1 franchise, executives said in a Monday morning conference call regarding the pharma giant's acquisition of San Diego-based Amylin and partnership agreement with AstraZeneca plc.
GlobeImmune Inc. filed for a $69 million initial public offering (IPO) to advance its cancer and infectious disease products developed using the Tarmogen platform.
Bristol Myers Squibb Co., of New York, will realize operating synergies and tax benefits in addition to gaining access to Amylin Pharmaceuticals Inc.'s GLP-1 franchise, executives said in a Monday morning conference call regarding the pharma giant's acquisition of San Diego-based Amylin and partnership agreement with AstraZeneca plc.
Sangart Inc.'s CEO Brian O'Callaghan first took on his C-level responsibilities at the age of 30 for a division of Merck Serono, but it wasn't official for two years because of his young age. "Investors thought at 30 years it was too big a risk for the CEO title," O'Callaghan told BioWorld Today. After 11 years, O'Callaghan has grown into the executive leadership position he took on so early.
Positive interim results from its GALAXY trial of ganetespib and docetaxel for non-small-cell lung cancer (NSCLC) ran Synta Pharmaceuticals Corp.'s stock price off a cliff Thursday.
Enrollment is now open in two clinical trials of XOMA Corp.'s gevokizumab for inflammatory diseases. One trial, a Phase III study, will evaluate gevokizumab for noninfectious uveitis, while a Phase II trial will look at gevokizumab for erosive osteoarthritis of the hand.
Valeant Pharmaceuticals Inc. continued its specialty pharma shopping spree with an agreement to acquire oral health firm OraPharma Inc. for $312 million with up to $114 million in additional milestones.
